SCHEMBL3304318

SCHEMBL3304318

Nc1ncnc2c1ncn2CCOC[PH](=O)O

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.66
SLC22A6 Q4U2R8 1/20 0.66
ADORA2A P29274 4/20 0.58
ADORA1 P30542 2/20 0.58
ADCY5 O95622 1/20 0.55
ADORA2B P29275 1/20 0.55
NSD3 Q9BZ95 6/20 0.54
NSD2 O96028 5/20 0.54
LMNA P02545 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA4 P22748 1/20 0.53
CA9 Q16790 1/20 0.53
HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19644453 0.85 SLC22A6 (0.63) FGFR1SLC22A6ADORA2AADORA1ADCY5
Adefovir SCHEMBL1262818 0.83 FGFR1 (0.91) FGFR1SLC22A6ADORA2AADORA1ADCY5
SCHEMBL2023978 0.82 FGFR1 (0.70) FGFR1SLC22A6ADORA2AADORA1ADCY5
SCHEMBL15046049 0.81 P2RY1 (0.53) FGFR1SLC22A6ADORA2AADORA1ADCY5
SCHEMBL18902347 0.80 FGFR1 (0.55) FGFR1SLC22A6ADORA2ANSD3NSD2
SCHEMBL1920120 0.80 FGFR1 (0.67) FGFR1SLC22A6ADORA2AADORA1ADCY5
SCHEMBL4364344 0.80 ADORA2A (0.70) FGFR1SLC22A6ADORA2AADORA1ADORA2B
SCHEMBL382916 0.80 FGFR1 (0.66) FGFR1SLC22A6ADORA2AADORA1ADORA2B
Adefovir SCHEMBL49373 0.80 FGFR1 (1.00) FGFR1SLC22A6ADORA2AADORA1ADCY5
Adefovir SCHEMBL29365535 0.80 FGFR1 (1.00) FGFR1SLC22A6ADORA2AADORA1ADCY5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017048956-A1 NUCLEOTIDE ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-03-23 WO disclosed
US-8884011-B2 Nucleotide analogues as precursor molecules for antivirals CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2014-11-11 US disclosed
US-8884011-B2 Nucleotide analogues as precursor molecules for antivirals CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2014-11-11 US disclosed
US-8884011-B2 Nucleotide analogues as precursor molecules for antivirals CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2014-11-11 US disclosed
WO-2014143643-A1 ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) 2014-09-18 WO disclosed
EP-1753762-B1 LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS METABASIS THERAPEUTICS INC (US) 2014-03-19 EP disclosed
US-20100099869-A1 NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2010-04-22 US disclosed
US-20100099869-A1 NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2010-04-22 US disclosed
US-20100099869-A1 NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) 2010-04-22 US disclosed
EP-2086990-A2 NOVEL NUCLEOTIDE ANALOGUES AS PERCURSOR MOLECULES FOR ANTIVIRALS Centre National De La Recherche Scientifique-CNRS (FR) 2009-08-12 EP disclosed
WO-2008056264-A2 NOVEL NUCLEOTIDE ANALOGUES AS PERCURSOR MOLECULES FOR ANTIVIRALS CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2008-05-15 WO disclosed
WO-2008056264-A2 NOVEL NUCLEOTIDE ANALOGUES AS PERCURSOR MOLECULES FOR ANTIVIRALS CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099869-A1 NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS NUDT1, P2RY1, HPRT1 FGFR1 3108/4885SLC22A6 988/4885ADORA2A 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.